Non-contraceptive benefits of hormonal and intrauterine reversible contraceptive methods
The DOI matches its Crossref record; 109 of the 109 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Most contraceptive methods present benefits beyond contraception; however, despite a large body of evidence, many healthcare professionals (HCPs), users and potential users are unaware of those benefits. This review evaluates the evidence for non-contraceptive benefits of hormonal and non-hormonal contraceptive methods. METHODS: We searched the medical publications in PubMed, POPLINE, CENTRAL, EMBASE and LILACS for relevant articles, on non-contraceptive benefits of the use of hormonal and intrauterine reversible contraceptive methods, which were published in English between 1980 and July 2014. Articles were identified using the following search terms: 'contraceptive methods', 'benefits', 'cancer', 'anaemia', 'heavy menstrual bleeding (HMB)', 'endometrial hyperplasia', 'endometriosis' and 'leiomyoma'. RESULTS: We identified, through the literature search, evidence that some combined oral contraceptives have benefits in controlling HMB and anaemia, reducing the rate of endometrial, ovarian and colorectal cancer and ectopic pregnancy as well as alleviating symptoms of premenstrual dysphoric disorder. Furthermore, the use of the levonorgestrel-releasing intrauterine system also controls HMB and anaemia and endometrial hyperplasia and cancer, reduces rates of endometrial polyps in users of tamoxifen and alleviates pain associated with endometriosis and adenomyosis. Depot medroxyprogesterone acetate controls crises of pain associated with sickle cell disease and endometriosis. Users of the etonogestrel-releasing contraceptive implant have the benefits of a reduction of pain associated with endometriosis, and users of the copper intrauterine device have reduced rates of endometrial and cervical cancer. CONCLUSIONS: Despite the high contraceptive effectiveness of many hormonal and intrauterine reversible contraceptive methods, many HCPs, users and potential users are concerned mainly about side effects and safety of both hormonal and non-hormonal contraceptive methods, and there is scarce information about the many benefits that these methods offer beyond contraception.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320 · cited 1×
“This kind of cell can block small blood vessels, impairing the transport of oxygen to the body’s tissues and provoking episodes of bone pain known as sickle pain crises, chronic complications and a life expectancy of 48 years on average (Platt et al., 1994).”
BackgroundRees, D. C., Williams, T. N., & Gladwin, M. T. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61029-x · Cited by 2,504
Population Estimates of Sickle Cell Disease in the U.S.
Hassell, K. L. (2010) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2009.12.022 · Cited by 1,211
Effectiveness of Long-Acting Reversible Contraception
Winner, B., Peipert, J. F., Zhao, Q., Buckel, C., Madden, T., Allsworth, J. E., & Secura, G. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110855 · Cited by 1,154 · cited 1×
“Despite the high contraceptive effectiveness of many contraceptive methods, especially long-acting reversible contraceptives (Winner et al., 2012; Bahamondes et al., 2014), many HCPs, users and potential users are concerned mainly about side effects and safety of many contraceptive methods, both hormonal and non-hormo…”
BackgroundCollaborative Group on Epidemiological Studies of Ovarian Cancer (2008) · The Lancet · doi:10.1016/s0140-6736(08)60167-1 · Cited by 822
Consensus on current management of endometriosis
Johnson, N. P., Hummelshoj, L., for the World Endometriosis Society Montpellier Consortium, Abrao, M. S., Adamson, G. D., Allaire, C., Amelung, V., Andersson, E., Becker, C., Birna Árdal, K. B., et al. (2013) · Human Reproduction · doi:10.1093/humrep/det050 · Cited by 558
Peart, W. S., Andrews, T. M., & Robertson, J. I. S. (1961) · The Lancet · doi:10.1016/s0140-6736(61)92247-4 · Cited by 405
Gierisch, J. M., Coeytaux, R. R., Urrutia, R. P., Havrilesky, L. J., Moorman, P. G., Lowery, W. J., Dinan, M., McBroom, A. J., Hasselblad, V., Sanders, G. D., et al. (2013) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0298 · Cited by 372
Petta, C. A., Ferriani, R. A., Abrao, M. S., Hassan, D., Rosa e Silva, J. C., Podgaec, S., & Bahamondes, L. (2005) · Human Reproduction · doi:10.1093/humrep/deh869 · Cited by 363
Self-citationInfection in sickle cell disease: A review
Booth, C., Inusa, B., & Obaro, S. K. (2010) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2009.03.010 · Cited by 357 · cited 1×
“The sickle crisis is the result of vaso-occlusion, which can also provoke retinopathy, nephropathy, asplenia, stroke and eventually infection (Booth et al., 2010; Rees et al., 2010).”
BackgroundLevonorgestrel‐releasing intrauterine device in the treatment of menorrhagia
ANDERSSON, J. K., & RYBO, G. (1990) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1990.tb16240.x · Cited by 356
Risk Factors for Young Premenopausal Women With Endometrial Cancer
Soliman, P. T., Oh, J. C., Schmeler, K. M., Sun, C. C., Slomovitz, B. M., Gershenson, D. M., Burke, T. W., & Lu, K. H. (2005) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000154151.14516.f7 · Cited by 351 · cited 2×
“Endometrial cancer is one of the most prevalent cancers in postmenopausal women (Soliman et al., 2005); however, it has also described in premenopausal women and even in young women (Parslov et al.”
BackgroundEfficacy of a New Low-Dose Oral Contraceptive With Drospirenone in Premenstrual Dysphoric Disorder
Yonkers, K. A., Brown, C., Pearlstein, T. B., Foegh, M., Sampson-Landers, C., & Rapkin, A. (2005) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000175834.77215.2e · Cited by 349
Hurskainen, R., Teperi, J., Rissanen, P., Aalto, A.-M., Grenman, S., Kivelä, A., Kujansuu, E., Vuorma, S., Yliskoski, M., & Paavonen, J. (2004) · JAMA · doi:10.1001/jama.291.12.1456 · Cited by 332
Moorman, P. G., Havrilesky, L. J., Gierisch, J. M., Coeytaux, R. R., Lowery, W. J., Peragallo Urrutia, R., Dinan, M., McBroom, A. J., Hasselblad, V., Sanders, G. D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.9021 · Cited by 303
Dossus, L., Allen, N., Kaaks, R., Bakken, K., Lund, E., Tjonneland, A., Olsen, A., Overvad, K., Clavel‐Chapelon, F., Fournier, A., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25050 · Cited by 296
Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: A meta-analysis
Iodice, S., Barile, M., Rotmensz, N., Feroce, I., Bonanni, B., Radice, P., Bernard, L., Maisonneuve, P., & Gandini, S. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.04.018 · Cited by 281
Pearlstein, T. B., Bachmann, G. A., Zacur, H. A., & Yonkers, K. A. (2005) · Contraception · doi:10.1016/j.contraception.2005.08.021 · Cited by 279
(2006) · Obstetrics & Gynecology · doi:10.1097/00006250-200606000-00055 · Cited by 277
Vercellini, P., Frontino, G., De Giorgi, O., Aimi, G., Zaina, B., & Crosignani, P. G. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(03)00608-3 · Cited by 263
Havrilesky, L. J., Moorman, P. G., Lowery, W. J., Gierisch, J. M., Coeytaux, R. R., Urrutia, R. P., Dinan, M., McBroom, A. J., Hasselblad, V., Sanders, G. D., et al. (2013) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e318291c235 · Cited by 258
Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device
Fedele, L., Bianchi, S., Raffaelli, R., Portuese, A., & Dorta, M. (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)00245-8 · Cited by 244 · cited 1×
“However, anecdotal reports indicate that the LNG-IUS should probably be replaced before its 5-year life span (Fedele et al., 1997; Fong and Singh, 1999; Bragheto et al., 2007; Cho et al., 2008).”
BackgroundHannaford, P. C., Iversen, L., Macfarlane, T. V., Elliott, A. M., Angus, V., & Lee, A. J. (2010) · BMJ · doi:10.1136/bmj.c927 · Cited by 243
Surgery versus medical therapy for heavy menstrual bleeding
Marjoribanks, J., Lethaby, A., & Farquhar, C. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003855.pub3 · Cited by 230
Gallos, I. D., Shehmar, M., Thangaratinam, S., Papapostolou, T. K., Coomarasamy, A., & Gupta, J. K. (2010) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2010.07.037 · Cited by 229
Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? 1☆
RODRIGUEZ, G., WALMER, D., CLINE, M., KRIGMAN, H., LESSEY, B., WHITAKER, R., DODGE, R., & HUGHES, C. (1998) · Journal of the Society for Gynecologic Investigation · doi:10.1016/s1071-5576(98)00017-3 · Cited by 210
Cancer Risk in Women Using the Levonorgestrel-Releasing Intrauterine System in Finland
Soini, T., Hurskainen, R., Grénman, S., Mäenpää, J., Paavonen, J., & Pukkala, E. (2014) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000000356 · Cited by 197
Safety concerns and health benefits associated with oral contraception
Burkman, R., Schlesselman, J. J., & Zieman, M. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.01.061 · Cited by 192
Impact of Progestin and Estrogen Potency in Oral Contraceptives on Ovarian Cancer Risk
Schildkraut, J. M. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.1.32 · Cited by 185
Kingman, C. E. C., Kadir, R. A., Lee, C. A., & Economides, D. L. (2004) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2004.00305.x · Cited by 182
Crosignani, P. G., Luciano, A., Ray, A., & Bergqvist, A. (2006) · Human Reproduction · doi:10.1093/humrep/dei290 · Cited by 179
Fraser, I. S., & McCarron, G. (1991) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/j.1479-828x.1991.tb02769.x · Cited by 173
Incidence of Endometrial Cancer in Relation to the Use of Oral Contraceptives
Weiss, N. S., & Sayvetz, T. A. (1980) · New England Journal of Medicine · doi:10.1056/nejm198003063021004 · Cited by 173
Levonorgestrel Intrauterine System versus Medical Therapy for Menorrhagia
Gupta, J., Kai, J., Middleton, L., Pattison, H., Gray, R., & Daniels, J. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1204724 · Cited by 172 · cited 9×
“Endometrial polyps in users of tamoxifen A systematic review (Chin et al., 2009) evaluated the use of the LNG-IUS among female users of tamoxifen in RCTs and showed that the LNG-IUS users presented a significant reduction in the incidence of endometrial polyps (Peto OR ¼ 0.14, 95% CI 0.03–0.61; Gardner et al., 2000, 2…”
BackgroundInfluentialJoffe, H., Cohen, L. S., & Harlow, B. L. (2003) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(03)00927-x · Cited by 171
Schlaff, W. D., Carson, S. A., Luciano, A., Ross, D., & Bergqvist, A. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.07.1315 · Cited by 168 · cited 4×
“More recently, Fraser et al. (2011) and Jensen et al. (2011) both showed, in randomized, doubleblinded, placebo controlled trials (RCTs), that the E2V/DNG COC significantly reduced HMB compared with placebo.”
MethodInfluentialMiddleton, L. J., Champaneria, R., Daniels, J. P., Bhattacharya, S., Cooper, K. G., Hilken, N. H., O'Donovan, P., Gannon, M., Gray, R., Khan, K. S., et al. (2010) · BMJ · doi:10.1136/bmj.c3929 · Cited by 167
Lockhat, F. B., Emembolu, J. O., & Konje, J. C. (2005) · Human Reproduction · doi:10.1093/humrep/deh650 · Cited by 166
Vercellini, P., De Giorgi, O., Oldani, S., Cortesi, I., Panazza, S., & Crosignani, P. G. (1996) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(96)70152-7 · Cited by 161 · cited 2×
“It was also observed that dysmenorrhoea was significantly worse with danazol and COC in comparison with DMPA after 1 year of treatment (Vercellini et al., 1996).”
BackgroundMethodGrigorieva, V., Chen-Mok, M., Tarasova, M., & Mikhailov, A. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(03)00175-4 · Cited by 161
Surgery versus medical therapy for heavy menstrual bleeding
Marjoribanks, J., Lethaby, A. E., & Farquhar, C. M. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003855.pub2 · Cited by 161
Risk factors among young women with endometrial cancer: A Danish case-control study
Parslov, M., Lidegaard, Ø., Klintorp, S., Pedersen, B. L., Jönsson, L., Eriksen, P. S., & Ottesen, B. (2000) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(00)70486-8 · Cited by 160 · cited 2×
“, 2005); however, it has also described in premenopausal women and even in young women (Parslov et al., 2000).”
BackgroundIncidence of Endometrial Cancer in Relation to the use of Oral Contraceptives
Weiss, N. S., & Sayvetz, T. A. (1980) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-198007000-00021 · Cited by 158
Castellsagué, X., Díaz, M., Vaccarella, S., de Sanjosé, S., Muñóz, N., Herrero, R., Franceschi, S., Meijer, C. J. L. M., & Bosch, F. X. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70223-6 · Cited by 149 · cited 1×
“A pooled analysis of 26 studies examined the protective effect of an IUD use upon cervical cancer risk (Castellsagué et al., 2011).”
BackgroundAhrendt, H.-J., Makalová, D., Parke, S., Mellinger, U., & Mansour, D. (2009) · Contraception · doi:10.1016/j.contraception.2009.03.018 · Cited by 147
Bragheto, A. M. D. S., Caserta, N. M. G., Bahamondes, L. G., & Petta, C. A. (2007) · Contraception · doi:10.1016/j.contraception.2007.05.091 · Cited by 146 · cited 2×
“Pain associated with endometriosis and adenomyosis (Petta et al., 2005; Bragheto et al., 2007; Cho et al., 2008; Tanmahasamut et al., 2012) is reduced by LNG-IUS.”
BackgroundSelf-citationKaunitz, A. M., Meredith, S., Inki, P., Kubba, A., & Sanchez‐Ramos, L. (2009) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e3181a1d3ce · Cited by 145
Kaunitz, A. M., Bissonnette, F., Monteiro, I., Lukkari-Lax, E., Muysers, C., & Jensen, J. T. (2010) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181ec622b · Cited by 145
Clinical effects of the levonorgestrel-releasing intrauterine device in patients with adenomyosis
Cho, S., Nam, A., Kim, H., Chay, D. B., Park, K., Cho, D. J., Park, Y., & Lee, B. S. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2007.10.798 · Cited by 143 · cited 3×
“Nevertheless, it has been described that the efficacy of the LNG-IUS on the reduction of uterine volume only begins to decrease after 2 years of placement (Cho et al., 2008).”
BackgroundEVENTS OF REPRODUCTIVE LIFE AND THE INCIDENCE OF EPITHELIAL OVARIAN CANCER
Risch, H. A., Weiss, N. S., Lyon, J. L., Daling, J. R., & Liff, J. M. (1983) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113523 · Cited by 143
Bayoglu Tekin, Y., Dilbaz, B., Altinbas, S. K., & Dilbaz, S. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.08.042 · Cited by 133
Donnez, J., Casanas‐Roux, F., Caprasse, J., Ferin, J., & Thomas, K. (1985) · Fertility and Sterility · doi:10.1016/s0015-0282(16)48496-7 · Cited by 133
Gardner, F., Konje, J., Abrams, K. R., Brown, L., Khanna, S., Al‐Azzawi, F., Bell, S., & Taylor, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03204-9 · Cited by 133
Walch, K., Unfried, G., Huber, J., Kurz, C., van Trotsenburg, M., Pernicka, E., & Wenzl, R. (2009) · Contraception · doi:10.1016/j.contraception.2008.07.017 · Cited by 128
Jensen, J. T., Parke, S., Mellinger, U., Machlitt, A., & Fraser, I. S. (2011) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3182118ac3 · Cited by 126
Oral contraceptives and premenstrual symptoms: Comparison of a 21/7 and extended regimen
Coffee, A. L., Kuehl, T. J., Willis, S., & Sulak, P. J. (2006) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2006.05.012 · Cited by 125
The Fallopian Tube as the Origin of High Grade Serous Ovarian Cancer: Review of a Paradigm Shift
Reade, C. J., Mcvey, R., Tone, A. A., Finlayson, S. J., McAlpine, J. N., Fung‐Kee‐Fung, M., & Ferguson, S. E. (2014) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(15)30659-9 · Cited by 124
Endometrial and ovarian cancer in women with Lynch syndrome: update in screening and prevention
Lu, K. H., & Daniels, M. S. (2013) · Familial Cancer · doi:10.1007/s10689-013-9664-5 · Cited by 121
Effects of anemia and iron deficiency on quality of life in women with heavy menstrual bleeding
Peuranpää, P., Heliövaara‐Peippo, S., Fraser, I., Paavonen, J., & Hurskainen, R. (2014) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.1111/aogs.12394 · Cited by 117
Oral contraceptives and colorectal cancer risk: a systematic review and meta-analysis
Bosetti, C., Bravi, F., Negri, E., & La Vecchia, C. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmp017 · Cited by 116
Continuous versus cyclic oral contraceptives for the treatment of endometriosis: a systematic review
Zorbas, K. A., Economopoulos, K. P., & Vlahos, N. F. (2015) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-015-3641-1 · Cited by 114
Effect of Depo-Provera® or Microgynon® on the painful crises of sickle cell anemia patients
Abood, M., de Castillo, Z., Guerrero, F., Espino, M., & Austin, K. L. (1997) · Contraception · doi:10.1016/s0010-7824(97)00156-x · Cited by 108 · cited 2×
“Another study compared the DMPA group, a COC group and a non-user group in 43 women with SCD (Abood et al., 1997).”
BackgroundTanmahasamut, P., Rattanachaiyanont, M., Angsuwathana, S., Techatraisak, K., Indhavivadhana, S., & Leerasiri, P. (2012) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31824264c3 · Cited by 105 · cited 4×
“The results showed that both the LNG-IUS and GnRH-a reduced pain scores according to the visual analogue scale without significant differences between both groups, although amenorrhoea occurred more rapidly among the GnRH users than the LNG-IUS users.”
BackgroundResultInfluentialGallos, I. D., Krishan, P., Shehmar, M., Ganesan, R., & Gupta, J. K. (2013) · Human Reproduction · doi:10.1093/humrep/det320 · Cited by 103
Dominick, S. A., Hickey, M., Chin, J., & Su, H. I. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007245.pub3 · Cited by 103
Mercorio, F., Simone, R. D., Sardo, A. D. S., Cerrota, G., Bifulco, G., Vanacore, F., & Nappi, C. (2003) · Contraception · doi:10.1016/s0010-7824(02)00522-x · Cited by 99
Bilian, X., Wu, S., Chong, J., Zeng, T., Han, L. I.-H., & Luukkainen, T. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(02)04913-0 · Cited by 95
Prediction of Regression and Relapse of Endometrial Hyperplasia With Conservative Therapy
Gallos, I. D., Ganesan, R., & Gupta, J. K. (2013) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e31828cb563 · Cited by 95
Soysal, S., & Soysal, M. E. (2004) · Gynecologic and Obstetric Investigation · doi:10.1159/000080932 · Cited by 89
Fong, Y. F., & Singh, K. (1999) · Contraception · doi:10.1016/s0010-7824(99)00075-x · Cited by 88 · cited 2×
“The first improvement could be attributed to direct effect of the LNG on foci of adenomyosis with decidualization and hypotrophy or atrophy of the endometrium (Fong and Singh, 1999; Haberal et al., 2006).”
BackgroundProgestin-Releasing Intrauterine Systems
Luukkainen, T., Pakarinen, P. I., & Toivonen, J. (2001) · Seminars in Reproductive Medicine · doi:10.1055/s-2001-18643 · Cited by 87
Current perspectives on oral contraceptive use
Burkman, R. T., Collins, J. A., SHULMAN, L. P., & Williams, J. (2001) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2001.117416 · Cited by 84
Self-citationOral contraceptive pill for heavy menstrual bleeding
Farquhar, C. M., & Brown, J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000154.pub2 · Cited by 83
DNA Damage Responses: p53 Induction, Cell Cycle Perturbations, and Apoptosis
Canman, C. E., Chen, C.-Y., Lee, M.-H., & Kastan, M. B. (1994) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1994.059.01.032 · Cited by 83
A population‐based case‐control study of endometrial cancer in shanghai, china
Shu, X., Brinton, L. A., Zheng, W., Gao, Y. T., Fan, J., & Fraumeni, J. F. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910490108 · Cited by 82 · cited 1×
“Only one study failed to show any significant protection (Shu et al., 1991), although even in this study there was a trend towards protection against endometrial cancer.”
Meta-Analysis of Intrauterine Device Use and Risk of Endometrial Cancer
Beining, R. M., Dennis, L. K., Smith, E., & Dokras, A. (2008) · Annals of Epidemiology · doi:10.1016/j.annepidem.2007.11.011 · Cited by 81
Fraser, I. S., Parke, S., Mellinger, U., Machlitt, A., Serrani, M., & Jensen, J. T. (2011) · The European Journal of Contraception & Reproductive Health Care · doi:10.3109/13625187.2011.591456 · Cited by 72
INTRAUTERINE CONTRACEPTION WITH LEVONORGESTREL: A COMPARATIVE RANDOMISED CLINICAL PERFORMANCE STUDY
Nilsson, C. G., Luukkainen, T., Díaz, J., & Allonen, H. O. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92031-6 · Cited by 70 · cited 1×
“Tapani Luukkainen, the Population Council’s International Committee for Contraception Research and the former Finnish company Leiras Oy (Nilsson et al., 1981; Luukkainen et al., 2001).”
BackgroundDepot medroxyprogesterone acetate and epithelial ovarian cancer: a multicentre case–control study
Wilailak, S., Vipupinyo, C., Suraseranivong, V., Chotivanich, K., Kietpeerakool, C., Tanapat, Y., Therasakvichya, S., Hamontri, S., Linasmita, V., Bunyapipat, S., et al. (2012) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2012.03298.x · Cited by 65
Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders
Lukes, A. S., Reardon, B., & Arepally, G. M. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.07.1315 · Cited by 64
Schaedel, Z. E., Dolan, G., & Powell, M. C. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.05.002 · Cited by 63
Abou-Setta, A. M., Al-Inany, H. G., & Farquhar, C. M. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005072.pub2 · Cited by 59 · cited 1×
“Despite the body of evidence regarding the improvement of pain associated with endometriosis and adenomyosis after the insertion of LNG-IUS, this kind of treatment is still considered to be a second line of therapy until more robust evidence can be obtained (Abou-Setta et al., 2006; Johnson et al., 2013).”
BackgroundHeliövaara‐Peippo, S., Hurskainen, R., Teperi, J., Aalto, A., Grénman, S., Halmesmäki, K. H., Jokela, M., Kivelä, A., Tomás, E. I., Tuppurainen, M. T., et al. (2013) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2013.08.041 · Cited by 58 · cited 2×
“It was found that both treatments were equally effective in the majority of the treated women at up to 10 years of follow-up (Hurskainen et al. 2004; Reid and Mukri, 2005; Heliövaara-Peippo et al., 2013), albeit that 50% of thewomen had a hysterectomy during the 10 years of observation and amenorrhoea was more common…”
BackgroundBahamondes, M. V., MONTEIRO, I. M. U., Castro, S., Espejo‐Arce, X., & Bahamondes, L. G. (2010) · Human Reproduction · doi:10.1093/humrep/deq043 · Cited by 57 · cited 1×
“The gold standard medical treatment is still the use of gonadotrophin-releasing hormone (GnRH) analogues; however, there is evidence showing that the insertion of an LNG-IUS is an adequate medical treatment for endometriosis and comparable with the use of GnRH with the advantage that it is possible to use it for up to…”
BackgroundSelf-citationSteroid hormones for contraception in women with sickle cell disease
Gómez, A. M., Grimes, D. A., Lopez, L. M., & Schulz, K. F. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006261.pub2 · Cited by 57 · cited 1×
“Although the use of hormonal contraceptives for SCD is controversial in the scientific literature (Manchikanti et al., 2007; Haddad et al., 2012), most types of contraceptives can be used in women with SCD.”
BackgroundSTEROID TREATMENT IN THE PREVENTION OF PAINFUL EPISODES IN SICKLE-CELL DISEASE
Isaacs, W. A., Effiong, C. E., & Ayeni, O. (1972) · The Lancet · doi:10.1016/s0140-6736(72)90359-5 · Cited by 57 · cited 1×
“Progesterone may stabilize the erythrocyte membrane and may prevent sickle crises (Isaacs and Hayhoe, 1967; Isaacs et al., 1972), while DMPA stabilizes the red cell membranes, making them less prone to sickling, thus causing reductions in pain crises (ACOG Practice Bulletin, 2006).”
BackgroundSHULMAN, L. P. (2011) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2011.06.057 · Cited by 56
Self-citationIntra‐uterine contraception and the risk of endometrial cancer
Castellsagué, X., Thompson, W. D., & Dubrow, R. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910540607 · Cited by 52 · cited 2×
“Although the results are conflicting, most of the studies showed a protective effect of the Cu-IUD regarding endometrial cancer (Castellsagué et al., 1993; Parazzini et al., 1994; Rosenblatt and Thomas, 1996; Hill et al., 1997; Sturgeon et al., 1997; Benshushan et al., 2002).”
BackgroundResultCheewadhanaraks, S., Choksuchat, C., Dhanaworavibul, K., & Liabsuetrakul, T. (2012) · Gynecologic and Obstetric Investigation · doi:10.1159/000337713 · Cited by 51 · cited 2×
“Furthermore, it has been observed that it is possible to treat patients after surgery for endometriosis with progestins and that this results in pain reduction (Vercellini et al., 2003; Cheewadhanaraks et al., 2012).”
BackgroundSteroid Hormones in Sickle-cell Disease
Isaacs, W. A., & Hayhoe, F. G. J. (1967) · Nature · doi:10.1038/2151139a0 · Cited by 50
Bahamondes, L. G., Bottura, B. F., Bahamondes, M. V., Gonçalves, M. P., Correia, V. M., Espejo‐Arce, X., de Sousa, M. H., MONTEIRO, I. M. U., & Fernandes, A. M. D. S. (2014) · Human Reproduction · doi:10.1093/humrep/deu191 · Cited by 49 · cited 1×
“Despite the high contraceptive effectiveness of many contraceptive methods, especially long-acting reversible contraceptives (Winner et al., 2012; Bahamondes et al., 2014), many HCPs, users and potential users are concerned mainly about side effects and safety of many contraceptive methods, both hormonal and non-hormo…”
BackgroundSelf-citationHale, G. E., Manconi, F., Luscombe, G. M., & Fraser, I. S. (2010) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e3181ca4b3a · Cited by 48
The levonorgestrel-releasing intrauterine system and endometriosis staging
Gomes, M. K. O., Ferriani, R. A., Silva, J. C. R. E., Silva, A. C. J. D. S. R. E., Vieira, C. S., & dos Reis, F. J. C. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.11.044 · Cited by 47 · cited 3×
“The results showed that both the LNG-IUS and GnRH-a reduced pain scores according to the visual analogue scale without significant differences between both groups, although amenorrhoea occurred more rapidly among the GnRH users than the LNG-IUS users.”
Resultde Sá Rosa e Silva, A. C. J., Rosa e Silva, J. C., Nogueira, A. A., Petta, C. A., Abrão, M. S., & Ferriani, R. A. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.02.082 · Cited by 46
IUD use and the risk of endometrial cancer
Benshushan, A., Paltiel, O., Rojansky, N., Brzezinski, A., & Laufer, N. (2002) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/s0301-2115(02)00153-7 · Cited by 44 · cited 1×
“Although the results are conflicting, most of the studies showed a protective effect of the Cu-IUD regarding endometrial cancer (Castellsagué et al., 1993; Parazzini et al., 1994; Rosenblatt and Thomas, 1996; Hill et al., 1997; Sturgeon et al., 1997; Benshushan et al., 2002).”
ResultLevonorgestrel intrauterine system: bleeding disorders and anticoagulant therapy
Kadir, R. A., & Chi, C. (2007) · Contraception · doi:10.1016/j.contraception.2007.01.005 · Cited by 44
Wong, A. W. Y., Chan, S. S. C., Yeo, W., Yu, M., & Tam, W. H. (2013) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e31828bf80c · Cited by 43
Kaunitz, A. M., Bissonnette, F., MONTEIRO, I. M. U., Lukkari‐Lax, E., DeSanctis, Y., & Jensen, J. T. (2012) · Contraception · doi:10.1016/j.contraception.2012.07.018 · Cited by 42
50 years of “The Pill”: celebrating a golden anniversary
Szarewski, A., Mansour, D., & SHULMAN, L. P. (2010) · Journal of Family Planning and Reproductive Health Care · doi:10.1783/147118910793048665 · Cited by 41
Self-citationVilos, G. A., Tureanu, V., Garcia, M., & Abu-Rafea, B. F. (2009) · Journal of Minimally Invasive Gynecology · doi:10.1016/j.jmig.2009.04.018 · Cited by 39
Eissa, A. A., Tuck, S. M., Rantell, K. R., & Stott, D. (2014) · Journal of Family Planning and Reproductive Health Care · doi:10.1136/jfprhc-2013-100763 · Cited by 35 · cited 1×
“A UK survey showed that 64% of women with SCD had experienced an unintended pregnancy; however, in a newer survey (Eissa et al., 2015), this declined to 53%.”
BackgroundIntrauterine device use and endometrial cancer risk
Sturgeon, S. R., Brinton, L. A., Berman, M. L., Mortel, R., Twiggs, L. B., Barrett, R. J., Wilbanks, G. D., & Lurain, J. R. (1997) · International Journal of Epidemiology · doi:10.1093/ije/26.3.496 · Cited by 34 · cited 2×
“Additionally, a more important limitation was the fact that only two studies (Rosenblatt and Thomas, 1996; Sturgeon et al., 1997) adjusted for COC use, which is a well-established protective factor (Gierisch et al.”
BackgroundResultAlternatives to risk-reducing surgery for ovarian cancer
Gadducci, A., Sergiampietri, C., & Tana, R. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt311 · Cited by 30
Bitzer, J., Amy, J., Beerthuizen, R. J. C. M., Birkhäuser, M., Bombas, T., Creinin, M. D., Darney, P. D., Vicente, L. F., Gemzell‐Danielsson, K., Imthurn, B., et al. (2013) · The European Journal of Contraception & Reproductive Health Care · doi:10.3109/13625187.2013.792637 · Cited by 28
Self-citationWhy Hormones Protect Against Large Bowel Cancer: Old Ideas, New Evidence
Newcomb, P. A., Pocobelli, G. S., & Chia, V. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-69080-3_24 · Cited by 28
Inki, P., Ling, X., Lee, B. S., Asif, S., & Kraemer, P. (2014) · International Journal of Women s Health · doi:10.2147/ijwh.s57470 · Cited by 20
Hoaglin, D. C., Filonenko, A., Glickman, M. E., Wasiak, R., & Gidwani, R. A. (2013) · European journal of medical research · doi:10.1186/2047-783x-18-17 · Cited by 19
Rodriguez, G. C., Barnes, H. J., Anderson, K. E., Whitaker, R. S., Berchuck, A., Petitte, J. N., Lancaster, J. M., Wenham, R. M., Turbov, J. M., Day, R., et al. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-12-0426 · Cited by 17
SHULMAN, L. P., & Dungan, J. S. (2010) · Cancer treatment and research · doi:10.1007/978-1-4419-6518-9_6 · Cited by 13
Self-citation
Cited by
An Update on Contraception in Polycystic Ovary Syndrome
Oguz, S. H., & Yildiz, B. O. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.958 · Cited by 76
“Several additional benefits of COCs have been shown in the general population [26,27].”
BackgroundToward an optimal contraception dosing strategy
Gavina, B. L. A., de los Reyes V, A. A., Olufsen, M. S., Lenhart, S., & Ottesen, J. T. (2023) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1010073 · Cited by 9
Metadata
- Authors
- Bahamondes, L., Valeria Bahamondes, M., & Shulman, L. P.
- Venue
- Human Reproduction Update
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-06-01
- Volume
- 21
- Issue
- 5
- Pages
- 640-651
- ISSN
- 1355-4786 (ISSN-L)
- 1460-2369
- OpenAlex
- W2100833087
- Cited by
- 193
- References
- 109
- FWCI
- 11.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.